1,3-dihydro-5-(o-fluorophenyl)-2H-1,4-benzodiazepine-2-thione | 303195-94-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 1,3-dihydro-5-(o-fluorophenyl)-2H-1,4-benzodiazepine-2-thione
• 英文别名: 5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepine-2-thione
• CAS: 303195-94-0
• 化学式: C₁₅H₁₁FN₂S
• 分子量: 270.33
• InChiKey: ICLUTYQZGYAMAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  56.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,3-dihydro-5-(o-fluorophenyl)-2H-1,4-benzodiazepine-2-thione 、 乙醛 在 哌啶 作用下， 以 乙二醇二甲醚 为溶剂， 生成 3-ethylidene-5-(2-fluorophenyl)-1,3-dihydro-2H-benzo[e][1,4]diazepine-2-thione
  参考文献：
  名称：

  Pyrazolobenzodiazepines: Part I. Synthesis and SAR of a potent class of kinase inhibitors

  摘要：

  A novel series of pyrazolobenzodiazepines 3 has been identified as potent inhibitors of cyclin-dependent kinase 2 (CDK2). Their synthesis and structure-activity relationships (SAR) are described. Representative compounds from this class reversibly inhibit CDK2 activity in vitro, and block cell cycle progression in human tumor cell lines. Further exploration has revealed that this class of compounds inhibits several kinases that play critical roles in cancer cell growth and division as well as tumor angiogenesis. Together, these properties suggest a compelling basis for their use as antitumor agents. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.079
• 作为产物：
  描述：

  5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one 在 劳森试剂 作用下， 以 乙二醇二甲醚 为溶剂， 生成 1,3-dihydro-5-(o-fluorophenyl)-2H-1,4-benzodiazepine-2-thione
  参考文献：
  名称：

  Pyrazolobenzodiazepines: Part I. Synthesis and SAR of a potent class of kinase inhibitors

  摘要：

  A novel series of pyrazolobenzodiazepines 3 has been identified as potent inhibitors of cyclin-dependent kinase 2 (CDK2). Their synthesis and structure-activity relationships (SAR) are described. Representative compounds from this class reversibly inhibit CDK2 activity in vitro, and block cell cycle progression in human tumor cell lines. Further exploration has revealed that this class of compounds inhibits several kinases that play critical roles in cancer cell growth and division as well as tumor angiogenesis. Together, these properties suggest a compelling basis for their use as antitumor agents. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.079

文献信息

• 6-(O-Halophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]-benzodiazepine
  申请人：The Upjohn Company

  公开号：US04018788A1

  公开（公告）日：1977-04-19

  6-(o-halophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]-benzodiazepines of the following formula: ##STR1## wherein the substituent "Hal" is either of the halogens having an atomic number up to 35, inclusive, i.e., fluoro, chloro or bromo, and their pharmacologically acceptable acid addition salts which are especially useful as muscle relaxing and anxiolylic agents.

  以下式子的6-(o-卤代苯基)-1-甲基-4H-s-三唑并[4,3-a][1,4]-苯二氮平，其中“Hal”取代基是原子序数为35及以下的卤素，即氟、氯或溴，以及它们的药理学上可接受的酸盐加合物，特别适用于肌肉松弛和抗焦虑药物。
• US4018788A
  申请人：——

  公开号：US4018788A

  公开（公告）日：1977-04-19
• Pyrazolobenzodiazepines: Part I. Synthesis and SAR of a potent class of kinase inhibitors
  作者：Jin-Jun Liu、Irena Daniewski、Qingjie Ding、Brian Higgins、Grace Ju、Kenneth Kolinsky、Fred Konzelmann、Christine Lukacs、Giacomo Pizzolato、Pamela Rossman、Amy Swain、Kshitij Thakkar、Chung-Chen Wei、Dorota Miklowski、Hong Yang、Xuefeng Yin、Peter M. Wovkulich

  DOI：10.1016/j.bmcl.2010.08.079

  日期：2010.10

  A novel series of pyrazolobenzodiazepines 3 has been identified as potent inhibitors of cyclin-dependent kinase 2 (CDK2). Their synthesis and structure-activity relationships (SAR) are described. Representative compounds from this class reversibly inhibit CDK2 activity in vitro, and block cell cycle progression in human tumor cell lines. Further exploration has revealed that this class of compounds inhibits several kinases that play critical roles in cancer cell growth and division as well as tumor angiogenesis. Together, these properties suggest a compelling basis for their use as antitumor agents. (c) 2010 Elsevier Ltd. All rights reserved.